TabsDetailsBasic DetailsDate: Friday, September 27, 2019Medical Product: Singulair, montelukastHealth Outcome(s): inpatient depressive disorderoutpatient depressive disorderself-harmsuicideMeeting Details: View the Advisory Committee Meeting Materials hereAdditional InformationRelated Assessment(s): Neuropsychiatric Events Following Montelukast Use: A Propensity Score Matched AnalysisRelated Link(s): FDA Safety Communication: FDA requires Boxed Warning for montelukast (Singulair)
